Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Recruiting now
Conditions studied: Chronic Mesenteric Ischemia, Median Arcuate Ligament Syndrome, Crohn Disease, Cholelithiasis
In brief
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
Key facts
- Study ID
- NCT06468774
- Run by
- Oslo University Hospital
- People needed
- 180
- Starts
- 2024-06-10
- Expected to finish
- 2037-05-31
- Last updated by the study team
- 2025-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Department of vascular surgery, Oslo University Hospital — Oslo, Oslo, Norway (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.